P2X7 receptor and renal diseases

LIU Hui; JI Xu

doi:10.11665/j.issn.1000-5048.20150519

Journal of China Pharmaceutical University > 2015 > 46(5): 629-634. > DOI: 10.11665/j.issn.1000-5048.20150519

LIU Hui, JI Xu. P2X7 receptor and renal diseases[J]. Journal of China Pharmaceutical University, 2015, 46(5): 629-634. DOI: 10.11665/j.issn.1000-5048.20150519

Citation:

LIU Hui, JI Xu. P2X7 receptor and renal diseases[J]. Journal of China Pharmaceutical University, 2015, 46(5): 629-634. DOI: 10.11665/j.issn.1000-5048.20150519

Citation:

LIU Hui, JI Xu. P2X7 receptor and renal diseases[J]. Journal of China Pharmaceutical University, 2015, 46(5): 629-634. DOI: 10.11665/j.issn.1000-5048.20150519

PDF (1303 KB)

P2X7 receptor and renal diseases

LIU Hui¹,
JI Xu²

More Information

Graphical Abstract

Abstract

Abstract

P2X7 receptor is a member of ATP-gated non-selective cation channels, and is one subtype family of the P2X purinergic receptor. Signaling pathways of P2X7 receptor couple with several key inflammatory molecules including IL-1β, IL-6 and COX-2, which suggests that P2X7 receptor plays a key role in the development of diseases via increased inflammation, indicating its potential as a novel therapeutic target. Recent studies show that P2X7 receptor has a relationship with renal diseases. This article reviews the effect of P2X7 receptor on renal diseases and its mechanism. P2X7 receptor may be a new drug target, and its selectivity antagonist may be a new therapeutic agent for the treatment of renal diseases.
- P2X7 receptor,
- renal diseases,
- inflammation,
- new therapeutic target

FullText(HTML)

References (47)

References

[1]	Surprenant A,North RA.Signaling at purinergic P2X receptors[J].Annu Rev Physiol,2009,71:333-359.
[2]	Von Kügelgen I,Harden TK.Molecular pharmacology,physiology,and structure of the P2Y receptors[J].Adv Pharmacol,2011,61:373-415.
[3]	Dal Ben D, Buccioni M, Lambertucci C, et al. Purinergic P2X receptors:structural models and analysis of ligand-target interaction[J].Eur J Med Chem,2015,89:561-580.
[4]	Surprenant A,Rassendren F,Kawashima E,et al.The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor(P2X7)[J].Science,1996,272(5262):735-738.
[5]	Rassendren F,Buell GN,Virginio C,et al.The permeabilizing ATP receptor,P2X7.Cloning and expression of a human cDNA[J].J Biol Chem,1997,272(9):5482-5486.
[6]	Costa-Junior HM,Sarmento Vieira F,Coutinho-Silva R.C terminus of the P2X7 receptor:treasure hunting[J].Purinergic Signal,2011,7(1):7-19.
[7]	North RA.Molecular physiology of P2X receptors[J].Physiol Rev,2002,82(4):1013-1067.
[8]	Di Virgilio F,Chiozzi P,Ferrari D,et al.Nucleotide receptors:an emerging family of regulatory molecules in blood cells[J].Blood,2001,97(3):587-600.
[9]	Kaczmarek-Hajek K,Lorinczi E,Hausmann R,et al.Molecular and functional properties of P2X receptors - recent progress and persisting challenges[J].Purinergic Signal,2012,8(3):375-417.
[10]	Skaper SD.Ion channels on microglia:therapeutic targets for neuroprotection[J].CNS Neurol Disord Drug Targets,2011,10(1):44-56.
[11]	Arulkumaran N,Unwin RJ,Tam FW.A potential therapeutic role for P2X7 receptor(P2X7R)antagonists in the treatment of inflammatory diseases[J].Expert Opin Investig Drugs,2011,20(7):897-915.
[12]	Birch RE,Schwiebert M,Peppiatt-Wildman CM,et al.Emerging key roles for P2X receptors in the kidney[J].Front Physiol,2013,4:262.
[13]	Solini A,Usuelli V,Fiorina P.The dark side of extracellular ATP in kidney diseases[J].J Am Soc Nephrol,2015.26(5):1007-1016.
[14]	Collo G,Neidhart S,Kawashima E,et al.Tissue distribution of the P2X7 receptor[J].Neuropharmacology,1997,36(9):1277-1283.
[15]	Ji X,Naito Y,Weng H,et al.P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate-salt hypertension[J].Am J Physiol Renal Physiol,2012,303(8):F1207-1215.
[16]	Arulkumaran N,Turner CM,Sixma ML,et al.Purinergic signaling in inflammatory renal disease[J].Front Physiol,2013,4:194.
[17]	Turner CM,Arulkumaran N,Singer M,et al.Is the inflammasome a potential therapeutic target in renal disease[J]? BMC Nephrology,2014,15:21.
[18]	Burnstock G,Nistri A,Khakh BS,et al.ATP-gated P2X receptors in health and disease[J].Front Cell Neurosci,2014,8:204.
[19]	Burnstock G.Purinergic signalling in the reproductive system in health and disease[J].Purinergic Signal,2014,10(1):157-187.
[20]	Guo C,Masin M,Qureshi OS,et al.Evidence for functional P2X4/P2X7 heteromeric receptors[J].Mol Pharmacol,2007,72(6):1447-1456.
[21]	Menzies RI,Unwin RJ,Dash RK,et al.Effect of P2X4 and P2X7 receptor antagonism on the pressure diuresis relationship in rats[J].Front Physiol,2013,4:305.
[22]	Booth JW,Tam FW,Unwin RJ.P2 purinoceptors:renal pathophysiology and therapeutic potential[J].Clin Nephrol,2012,78(2):154-163.
[23]	Ferrari D,Pizzirani C,Adinolfi E,et al.The P2X7 receptor:a key player in IL-1 processing and release[J].J Immunol,2006,176(7):3877-3883.
[24]	Jacobson KA,Jarvis MF,Williams M.Purine and pyrimidine(P2)receptors as drug targets[J].J Med Chem,2002,45(19):4057-4093.
[25]	Gunosewoyo H,Kassiou M.P2X purinergic receptor ligands:recently patented compounds[J].Expert Opin Ther Pat,2010,20(5):625-646.
[26]	North RA,Jarvis MF.P2X receptors as drug targets[J].Mol Pharmacol,2013,83(4):759-769.
[27]	Di Virgilio F.Novel data point to a broader mechanism of action of oxidized ATP:the P2X7 receptor is not the only target[J].Br J Pharmacol,2003,140(3):441-443.
[28]	Donnelly-Roberts DL,Namovic MT,Han P,et al.Mammalian P2X7 receptor pharmacology:comparison of recombinant mouse,rat and human P2X7 receptors[J].Br J Pharmacol,2009,157(7):1203-1214.
[29]	Donnelly-Roberts DL,Jarvis MF.Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states[J].Br J Pharmacol,2007,151(5):571-579.
[30]	Nelson DW,Gregg RJ,Kort ME,et al.Structure-activity relationship studies on a series of novel,substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists[J].J Med Chem,2006,49(12):3659-3666.
[31]	Honore P,Donnelly-Roberts D,Namovic MT,et al.A-740003[N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide],a novel and selective P2X7 receptor antagonist,dose-dependently reduces neuropathic pain in the rat[J].J Pharmacol Exp Ther,2006,319(3):1376-1385.
[32]	Turner CM,Tam FW,Lai PC,et al.Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis[J].Nephrol Dial Transplant,2007,22(2):386-395.
[33]	Vonend O,Turner CM,Chan CM,et al.Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models[J].Kidney Int,2004,66(1):157-166.
[34]	Ji X,Naito Y,Hirokawa G,et al.P2X(7)receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats[J].Hypertens Res,2012,35(2):173-179.
[35]	Xu H,Liang SD.Effect of P2X7 receptor on inflammatory diseases and its mechanism[J].Acta Physiol Sinica(生理学报),2013,65(2):244-252.
[36]	Solini A,Menini S,Rossi C,et al.The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet:possible role of NLRP3 inflammasome activation[J].J Pathol,2013,231(3):342-353.
[37]	Taylor SR,Turner CM,Elliott JI,et al.P2X7 deficiency attenuates renal injury in experimental glomerulonephritis[J].J Am Soc Nephrol,2009,20(6):1275-1281.
[38]	Zhao J,Wang H,Dai C,et al.P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway[J].Arthritis Rheum,2013,65(12):3176-3185.
[39]	Goncalves RG,Gabrich L,Rosario A Jr,et al.The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice[J].Kidney Int,2006,70(9):1599-1606.
[40]	Yan Y,Bai J,Zhou X,et al.P2X7 receptor inhibition protects against ischemic acute kidney injury in mice[J].Am J Physiol Cell Physiol,2015,308(6):C463-472.
[41]	Menzies RI, Unwin RJ, Bailey MA. Renal P2 receptors and hypertension[J].Acta Physiol(Oxf),2015,213(1):232-241.
[42]	Ponnusamy M,Ma L,Gong R,et al.P2X7 receptors mediate deleterious renal epithelial-fibroblast cross talk[J].Am J Physiol Renal Physiol,2011,300(1):F62-70.
[43]	Harada H,Chan CM,Loesch A,et al.Induction of proliferation and apoptotic cell death via P2Y and P2X receptors,respectively,in rat glomerular mesangial cells[J].Kidney Int,2000,57(3):949-958.
[44]	Schwiebert EM,Kishore BK.Extracellular nucleotide signaling along the renal epithelium[J].Am J Physiol Renal Physiol,2001,280(6):F945-963.
[45]	Guan Z,Fellner RC,Van Beusecum J,et al.P2 receptors in renal autoregulation[J].Curr Vasc Pharmacol,2014,12(6):818-828.
[46]	Burnstock G,Ralevic V.Purinergic signaling and blood vessels in health and disease[J].Pharmacol Rev,2014,66(1):102-192.
[47]	Wiley JS,Sluyter R,Gu BJ,et al.The human P2X7 receptor and its role in innate immunity[J].Tissue Antigens,2011,78(5):321-332.

Cited By

Get Citation

PDF

XML

Article views (1065) PDF downloads (1941)

Turn off MathJax

Article Contents

Abstract

References

P2X7 receptor and renal diseases

Abstract

References

Catalog

Export File

Citation

Format

Content